Mammary artery versus saphenous vein grafts: assessment of basic fibroblast growth factor receptors

Ann Thorac Surg. 1994 Aug;58(2):308-10; discussion 310-1. doi: 10.1016/0003-4975(94)92198-9.

Abstract

Neointimal hyperplasia limits the long-term patency of saphenous vein grafts (SVGs), but is notably absent from most internal mammary artery (IMA) grafts. Basic fibroblast growth factor (bFGF) is a local endothelial and vascular smooth muscle mitogen known to be involved in the pathogenesis of neointimal hyperplasia. This study used an animal model to compare the number of available high-affinity (HAR) and low-affinity (LAR) bFGF receptors in SVGs and IMA grafts and to determine whether distention injury causes an increase in receptor availability. The IMA and SVG specimens were harvested from 12 dogs and distended at 25 or 200 mm Hg for 15 minutes, and then the bFGF receptor uptake was measured in them using iodine 125-labeled bFGF. In the IMA conduits distended at low pressure, there were 2.54 +/- 0.10 (mean +/- standard error of the mean) HARs per mm2 of intimal surface area available and 5.19 +/- 0.40 LARs per mm2. High-pressure distention significantly (p < 0.001) increased the number of available HARs to 5.06 +/- 0.27 per mm2 and of LARs to 7.27 +/- 0.042 per mm2. At low pressure, the SVGs had significantly (p < 0.001) more HARs (9.14 +/- 0.84 per mm2) and LARs (18.2 +/- 0.57 per mm2) available than did the IMA conduits, and high pressure significantly (p < 0.001) increased the number of HARs available in SVGs to 24.1 +/- 2.43 per mm2 and the number of LARs to 44.7 +/- 2.34 per mm2.(ABSTRACT TRUNCATED AT 250 WORDS)

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Coronary Artery Bypass / methods*
  • Dogs
  • Hyperplasia
  • Internal Mammary-Coronary Artery Anastomosis*
  • Mammary Arteries / metabolism
  • Receptors, Fibroblast Growth Factor / analysis*
  • Saphenous Vein / metabolism
  • Saphenous Vein / pathology
  • Saphenous Vein / transplantation*
  • Tunica Intima / pathology

Substances

  • Receptors, Fibroblast Growth Factor